FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955149622> ?p ?o ?g. }

• W2955149622 abstract "Background: Immune therapies have shown great promise for some cancers. To date, pancreatic ductal adenocarcinomas (PDAC) have been largely resistant to immunotherapeutic approaches in part due to their exclusion of tumor infiltrating lymphocytes. The mechanisms by which this exclusion occurs are not well-characterized but are thought to involve both innate and adaptive immune responses. Methods: The primary objective of this study was to investigate how dual anti-PD-1/anti-CSF1R therapy changes the tumor immune cell niche and tumor growth in an allograft version of the KPC mouse model of PDAC (Pdx-1-Cre; LSL-KrasG12D; LSL-Trp53 R172H). Anti-PD1 therapy in the form of monoclonal antibody from BioXCell® was dosed twice weekly via intraperitoneal injections at 200µg/mouse. Anti-CSF1R in the form of the small-molecule inhibitor BLZ945 from Selleckchem® was dosed daily via oral gavage at 200 mg/kg. Human THP-1 cells differentiated and polarized to macrophages were used for viability and gene expression analyses. Results: In B6 recipient mice, the combination anti-PD-1 plus BLZ945 resulted in reduced percent tumor volume change (11% ±17) versus vehicle treated controls (121% ±174) (p=0.02). Flow cytometry of the spleens of tumor-bearing mice demonstrated an increase in conventional dendritic cells with combination treatment compared to controls (15.3 ±2.3% vs 8.3 ±0.6%, respectively; p=0.02). Mice lacking conventional dendritic cells (B6.BATF3-/-) had an increased percent tumor volume change (84% ±78) compared to B6 wild type mice (11% ±16) (p=0.01) when receiving combination treatment. IHC staining of allografted tumors revealed a trend towards increased infiltrating CD8+ T cells/hpf in B6 wild type mice treated with anti-PD-1 or combination therapy (21±24/hpf) compared to control treated mice (11±18/hpf). A similar trend was observed in B6.BATF3-/- mice (2.9±4.4/hpf vs 0.5±0.50/hpf); however, the magnitude was greatly reduced compared to B6 wild type mice. Interestingly, BLZ945 treated tumors did not show evidence of statistically significant reduced macrophage recruitment in vivo (268 vs 241, p=0.16). Macrophage viability in vitro was also unaffected by BLZ945 treatment (fold change in viability 0.03, p=0.6). Preferential changes in macrophage polarization in vitro were observed, with significant reductions in M2 polarization markers Arg-1, YM-1, and CD206 (p= 0.0005, 0.0029, and 0.012, respectively). Conclusions: The combination of an anti-PD-1 agent in combination with inhibition of the macrophage-predominant cytokine, anti-CSF1R, slows PDAC tumor growth in a conventional dendritic cell-dependent manner. Further characterization of the interplay between innate and adaptive immune cells upon immunotherapy treatment should be investigated to increase the efficacy of these therapeutics. Citation Format: Chelsie K. Sievers, Philip B. Emmerich, Hanna R. Rainiero, Connor Maloney, Rosabella Pitera, Cheri A. Pasch, Linda Clipson, Kristina A. Matkowskyj, Fotis Asimakopoulos, Dustin A. Deming. BLZ945 and anti-PD-1 combination immunotherapy modulates the immune landscape in pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3209." @default.
• W2955149622 created "2019-07-12" @default.
• W2955149622 creator A5030932932 @default.
• W2955149622 creator A5047282786 @default.
• W2955149622 creator A5048019436 @default.
• W2955149622 creator A5055054782 @default.
• W2955149622 creator A5059310641 @default.
• W2955149622 creator A5069462238 @default.
• W2955149622 creator A5078538809 @default.
• W2955149622 creator A5088883370 @default.
• W2955149622 creator A5091428111 @default.
• W2955149622 creator A5091660729 @default.
• W2955149622 date "2019-07-01" @default.
• W2955149622 modified "2023-09-26" @default.
• W2955149622 title "Abstract 3209: BLZ945 and anti-PD-1 combination immunotherapy modulates the immune landscape in pancreatic ductal adenocarcinoma" @default.
• W2955149622 doi "https://doi.org/10.1158/1538-7445.am2019-3209" @default.
• W2955149622 hasPublicationYear "2019" @default.
• W2955149622 type Work @default.
• W2955149622 sameAs 2955149622 @default.
• W2955149622 citedByCount "0" @default.
• W2955149622 crossrefType "proceedings-article" @default.
• W2955149622 hasAuthorship W2955149622A5030932932 @default.
• W2955149622 hasAuthorship W2955149622A5047282786 @default.
• W2955149622 hasAuthorship W2955149622A5048019436 @default.
• W2955149622 hasAuthorship W2955149622A5055054782 @default.
• W2955149622 hasAuthorship W2955149622A5059310641 @default.
• W2955149622 hasAuthorship W2955149622A5069462238 @default.
• W2955149622 hasAuthorship W2955149622A5078538809 @default.
• W2955149622 hasAuthorship W2955149622A5088883370 @default.
• W2955149622 hasAuthorship W2955149622A5091428111 @default.
• W2955149622 hasAuthorship W2955149622A5091660729 @default.
• W2955149622 hasConcept C121608353 @default.
• W2955149622 hasConcept C159654299 @default.
• W2955149622 hasConcept C203014093 @default.
• W2955149622 hasConcept C2777701055 @default.
• W2955149622 hasConcept C2781182431 @default.
• W2955149622 hasConcept C502942594 @default.
• W2955149622 hasConcept C542903549 @default.
• W2955149622 hasConcept C54355233 @default.
• W2955149622 hasConcept C553184892 @default.
• W2955149622 hasConcept C86803240 @default.
• W2955149622 hasConcept C8891405 @default.
• W2955149622 hasConceptScore W2955149622C121608353 @default.
• W2955149622 hasConceptScore W2955149622C159654299 @default.
• W2955149622 hasConceptScore W2955149622C203014093 @default.
• W2955149622 hasConceptScore W2955149622C2777701055 @default.
• W2955149622 hasConceptScore W2955149622C2781182431 @default.
• W2955149622 hasConceptScore W2955149622C502942594 @default.
• W2955149622 hasConceptScore W2955149622C542903549 @default.
• W2955149622 hasConceptScore W2955149622C54355233 @default.
• W2955149622 hasConceptScore W2955149622C553184892 @default.
• W2955149622 hasConceptScore W2955149622C86803240 @default.
• W2955149622 hasConceptScore W2955149622C8891405 @default.
• W2955149622 hasLocation W29551496221 @default.
• W2955149622 hasOpenAccess W2955149622 @default.
• W2955149622 hasPrimaryLocation W29551496221 @default.
• W2955149622 hasRelatedWork W1160892457 @default.
• W2955149622 hasRelatedWork W1495788311 @default.
• W2955149622 hasRelatedWork W1551112729 @default.
• W2955149622 hasRelatedWork W2011757360 @default.
• W2955149622 hasRelatedWork W2013226620 @default.
• W2955149622 hasRelatedWork W2349867493 @default.
• W2955149622 hasRelatedWork W2395000660 @default.
• W2955149622 hasRelatedWork W2476540671 @default.
• W2955149622 hasRelatedWork W2476999556 @default.
• W2955149622 hasRelatedWork W2493130567 @default.
• W2955149622 hasRelatedWork W2502634075 @default.
• W2955149622 hasRelatedWork W2506571864 @default.
• W2955149622 hasRelatedWork W2740769512 @default.
• W2955149622 hasRelatedWork W2811298511 @default.
• W2955149622 hasRelatedWork W2885507154 @default.
• W2955149622 hasRelatedWork W2954295954 @default.
• W2955149622 hasRelatedWork W2968266738 @default.
• W2955149622 hasRelatedWork W2982372328 @default.
• W2955149622 hasRelatedWork W3011773444 @default.
• W2955149622 hasRelatedWork W3081641895 @default.
• W2955149622 isParatext "false" @default.
• W2955149622 isRetracted "false" @default.
• W2955149622 magId "2955149622" @default.
• W2955149622 workType "article" @default.